BGC 200166

Drug Profile

BGC 200166

Alternative Names: BGC20-0166; COL-132

Latest Information Update: 20 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BTG
  • Class
  • Mechanism of Action Serotonin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Sleep apnoea syndrome

Most Recent Events

  • 20 Mar 2014 Discontinued - Phase-II for Sleep apnoea syndrome in USA (unspecified route)
  • 02 Apr 2009 BTG is seeking partnership opportunities to further develop BGC 200166 in Sleep apnoea syndrome
  • 10 Apr 2008 Additional efficacy data from a Phase-II trial in Sleep apnoea syndrome released by BTG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top